A prediction from a qualified physician that suggests the likely result of a patient’s cancer is known as a prognosis. The doctor’s prognosis is based on the statistics gathered from others with both the same diagnoses of cancer and stage of which the disease is at. It is only an assessment, however. While many others have outlived their prognoses there is still the possibility of outliving a prognosis by discussing the topic with a doctor.
For those who are diagnosed with mesothelioma, there is often a grim prognosis. However, a patient’s quality of life and life expectancy can be improved when making informed decisions regarding their overall health habits and medical treatment options.
Prognosis of Mesothelioma
Median Life Expectancy for Pleural Mesothelioma Patients by Stage
|Median Life Expectancy||Median Life Expectancy|
|Stage 1||21 months|
|Stage 2||19 months|
|Stage 3||16 months|
|Stage 4||12 months|
Survival Rates of Patients with Pleural Mesothelioma
|Years After Diagnosis||Survival Rate|
Mesothelioma Prognosis Terminology
Defining Mesothelioma Prognosis
What does Prognosis mean?
What are Biological Factors?
Certain factors in a patient’s prognosis – including their age and gender, specifications of their blood characteristics, type of cancer cell present, and the stage at which a patient is at – are unchangeable.
The prognosis is typically more favorable for younger patients as the aggressive therapies that are used to treat cancers are better handled by their immune systems. The general physical health and fitness of younger people is usually better than that of older people which may be more beneficial during recovery from cancer treatment(s).
While 43 percent of patients (younger than 45) survived five years after diagnosis, only 5.7 percent of patients (65 years of age or older) reached the same point; according to statistics, age makes a difference.
Women with pleural mesothelioma have a better prognosis compared to men with pleural mesothelioma. It is suspected by researchers that hormonal differences can play a role in better treatment for women.
A data review from the National Cancer Institute shows that the 5-year survival rate for women is nearly three times higher for men.
A prognosis may be impacted by specific biomarkers found in blood. Such biomarkers that have varying implications towards prognoses include COX-2, fibulin-3, MIB-1, platelet counts, and white blood cells (WBC) – for instance:
Unlike sarcomatoid cells, which easily spread apart, epithelial cells stick together more closely. Consequently, the favored prognosis is carried with mesothelioma of the epithelial cell type as it responds better to treatment than sarcomatoid cells.
A combination of the two are known as biphasic cells. The prognosis with this cell type depends on the present cell ratio – if there is a higher epithelial cell count, there is likely to be an improved prognosis.
The progression of cancer is determined with the help of staging. In stages 1 and 2, the cancer is localized and small, while in stages 3 and 4, the cancer has dispersed to other parts of the body and grown.
While tumors that have dispersed are much harder to operate on, larger tumors do not respond to chemotherapy and radiation therapy as well anymore.
Consider Participation in Clinical Trials
Learn About Established Treatments
By selecting cancer treatments, pleural mesothelioma patients are able to improve their prognosis. However, the type of tumor cell, overall health, and stage at which a patient is diagnosed are all dependable factors that can have some effect on the prognosis.
The multimodal approach is beneficial for patients with epithelial cell types and early stage tumors. This approach entails of a combination of surgery, radiation therapy, and chemotherapy. Although each of these treatments can alleviate symptoms on its own, combinations of each can correspond to better life expectancies compared to any singular treatment. Not everyone qualifies for this aggressive approach, however.
Pleural Mesothelioma Median Survival Period According to a 2011 Study
|With Surgical Treatment||710 days|
|Without Surgical Treatment||288 days|
The goal of palliative treatments is to alleviate symptoms of cancer and improve quality of life, which is generally the most beneficial action for patients with late-stage pleural mesothelioma. Although palliative treatments assist with pain and discomfort reduction, they can also extend survival.
Reduce Your Stress
How an individuals’ body responds to cancer treatment can be reliant on their overall health, so leading a low-stress lifestyle could be immensely beneficial. Make note of any stressors and determine what can be done to manage them in order to reduce anxiety or frustrations that you or a loved one may experience.